BR0016696A - Pseudo-dipeptìdeos acilados inéditos portadores de um ramo auxiliar funcionalizado, processos para a sua preparação e composições farmacêuticas contendo-os - Google Patents

Pseudo-dipeptìdeos acilados inéditos portadores de um ramo auxiliar funcionalizado, processos para a sua preparação e composições farmacêuticas contendo-os

Info

Publication number
BR0016696A
BR0016696A BR0016696-0A BR0016696A BR0016696A BR 0016696 A BR0016696 A BR 0016696A BR 0016696 A BR0016696 A BR 0016696A BR 0016696 A BR0016696 A BR 0016696A
Authority
BR
Brazil
Prior art keywords
pseudo
functionalized
processes
preparation
pharmaceutical compositions
Prior art date
Application number
BR0016696-0A
Other languages
English (en)
Inventor
Jacques Bauer
Olivier Richard Martin
Sylvain Rodriguez
Original Assignee
Om Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Pharma filed Critical Om Pharma
Publication of BR0016696A publication Critical patent/BR0016696A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PSEUDO-DIPEPTìDEOS ACILADOS INéDITOS PORTADORES DE UM RAMO AUXILIAR FUNCIONALIZADO, PROCESSOS PARA A SUA PREPARAçãO E COMPOSIçõES FARMACêUTICAS CONTENDO-OS". O objetivo da invenção se refere especificamente a pseudo-dipeptídeos que derivam de aminoácidos funcionalizados, tendo cadeias de ácidos graxos fixados sob forma de amida sobre as funções amina do pseudo-dipeptídeo, sendo uma das suas extremidades portadora de um ramo auxiliar funcionalizado e consistindo a outra extremidade em um grupamento ácido sob forma neutra ou com carga. Os compostos da presente invenção possuem propriedades imuno-moduladoras como adjuvantes. Os compostos da invenção podem além disso ser enxertados sobre um antígeno para modular a resposta imunitária ou ser igualmente enxertados sobre um veículo farmacológico para melhorar a sua ação terapêutica ou seu direcionamento. Os compostos da invenção por este motivo encontram utilização na medicina humana e veterinária como agentes imunizantes e como instrumento de diagnóstico.
BR0016696-0A 1999-12-22 2000-12-21 Pseudo-dipeptìdeos acilados inéditos portadores de um ramo auxiliar funcionalizado, processos para a sua preparação e composições farmacêuticas contendo-os BR0016696A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1999/002038 WO2001046127A1 (fr) 1999-12-22 1999-12-22 Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
PCT/FR2000/003650 WO2001046126A1 (fr) 1999-12-22 2000-12-21 Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise

Publications (1)

Publication Number Publication Date
BR0016696A true BR0016696A (pt) 2004-06-22

Family

ID=11004948

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016696-0A BR0016696A (pt) 1999-12-22 2000-12-21 Pseudo-dipeptìdeos acilados inéditos portadores de um ramo auxiliar funcionalizado, processos para a sua preparação e composições farmacêuticas contendo-os

Country Status (16)

Country Link
US (3) US7799762B2 (pt)
EP (1) EP1242365A1 (pt)
JP (1) JP4902924B2 (pt)
CN (2) CN1434795B (pt)
AR (1) AR035024A1 (pt)
AU (3) AU1581400A (pt)
BR (1) BR0016696A (pt)
CA (1) CA2395197C (pt)
CZ (1) CZ20022194A3 (pt)
HU (1) HUP0204531A3 (pt)
LV (1) LV12886B (pt)
PL (1) PL208584B1 (pt)
RU (1) RU2275378C2 (pt)
SK (1) SK287514B6 (pt)
TW (1) TWI237022B (pt)
WO (2) WO2001046127A1 (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915238B2 (en) 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
WO2001046127A1 (fr) * 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
EP2269638A3 (en) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
RU2396960C2 (ru) * 2004-07-23 2010-08-20 Ом Фарма Комбинированная противоопухолевая терапия и фармацевтические композиции для нее
WO2006095270A1 (en) * 2005-03-10 2006-09-14 Om Pharma Combination anticancer therapy or om-174 and pharmaceutical compositions therefor
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
AR054020A1 (es) 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
CN103285392A (zh) 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101515078B1 (ko) 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2007102081A2 (en) * 2006-03-09 2007-09-13 Om Pharma Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
EP2476433A1 (en) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
PT2422810E (pt) 2006-07-17 2014-12-03 Glaxosmithkline Biolog Sa Vacina da gripe
US9364525B2 (en) 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2690708A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine
WO2009117035A1 (en) 2007-12-19 2009-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
JP5711972B2 (ja) 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
ES2553113T3 (es) 2008-04-16 2015-12-04 Glaxosmithkline Biologicals S.A. Vacuna
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20110293660A1 (en) 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
PE20110992A1 (es) 2009-02-17 2012-02-12 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende un antigeno del virus del dengue
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
HUE028085T2 (en) 2009-06-24 2016-11-28 Glaxosmithkline Biologicals Sa Recombinant RSV antigens
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP5774010B2 (ja) 2009-09-25 2015-09-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザウイルスのための免疫拡散アッセイ
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
EP2627352B1 (en) 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Cytomegalovirus gb antigen
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
CN103533953A (zh) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 针对肺炎链球菌的疫苗
US20130144540A1 (en) * 2011-12-06 2013-06-06 Palo Alto Research Center Incorporated Constrained de novo sequencing of peptides
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
BE1022174B1 (fr) 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
MX2016001695A (es) 2013-08-05 2016-05-02 Glaxosmithkline Biolog Sa Composiciones inmunogenas de combinacion.
JP6851827B2 (ja) 2013-08-30 2021-03-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細胞培養中でのウイルスの大規模製造
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015165480A1 (en) 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
MX384992B (es) 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
AU2015384786B2 (en) 2015-03-03 2020-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
WO2016207408A1 (en) 2015-06-26 2016-12-29 Institute For Research In Biomedicine Novel vaccines in prevention and treatment of malaria
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
WO2018193063A2 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
JP2023553854A (ja) 2020-12-02 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ドナー鎖補完性ｆｉｍｈ
WO2022162012A2 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2022161598A1 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
CN118510790A (zh) 2021-12-13 2024-08-16 美国政府(由卫生和人类服务部的部长所代表) 噬菌体λ-疫苗系统
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2460290A1 (fr) * 1979-06-29 1981-01-23 Rhone Poulenc Ind Nouveaux tetra- ou pentapeptides, leur preparation et les medicaments qui les contiennent
DE4119856A1 (de) * 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
DE4123365A1 (de) 1991-07-15 1993-01-21 Sandoz Ag Acylaminopentansaeurederivate, verfahren zu ihrer herstellung und ihre verwendung
DE4123366A1 (de) 1991-07-15 1993-01-21 Sandoz Ag Acylpentanoylamidoglycinderivate, verfahren zu ihrer herstellung und ihre verwendung
JPH06206893A (ja) * 1992-09-07 1994-07-26 Suntory Ltd 新規なジサッカライド誘導体
FR2701948B1 (fr) * 1993-02-22 1996-07-26 Exsymol Sa Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires.
EP0668289A4 (en) * 1993-09-07 1998-10-21 Suntory Ltd NEW DISACCHARIDE DERIVATIVE.
ES2194666T3 (es) * 1993-09-10 2003-12-01 Petrovax Inc Portador inmunoestimulante para vacunas.
PL181241B1 (pl) * 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
RU2141483C1 (ru) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
GB9727123D0 (en) 1997-12-22 1998-02-25 Int Centre Genetic Eng & Bio Synthesis of diamines
CN1168702C (zh) * 1998-06-30 2004-09-29 Om药业 酰基-二肽类化合物,其制备方法以及含有前述化合物的药物组合物
WO2001046127A1 (fr) * 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise

Also Published As

Publication number Publication date
RU2275378C2 (ru) 2006-04-27
AU1581400A (en) 2001-07-03
SK9202002A3 (en) 2003-04-01
CN101164543B (zh) 2012-03-21
TWI237022B (en) 2005-08-01
US20030203852A1 (en) 2003-10-30
SK287514B6 (sk) 2010-12-07
AU2006202085B2 (en) 2012-01-19
AU2006202085C1 (en) 2012-07-05
CN1434795A (zh) 2003-08-06
CA2395197C (fr) 2013-03-26
CN101164543A (zh) 2008-04-23
PL356405A1 (en) 2004-06-28
JP2003518086A (ja) 2003-06-03
CA2395197A1 (fr) 2001-06-28
CZ20022194A3 (cs) 2002-11-13
JP4902924B2 (ja) 2012-03-21
HUP0204531A3 (en) 2004-12-28
US20050192232A1 (en) 2005-09-01
LV12886B (en) 2003-03-20
PL208584B1 (pl) 2011-05-31
US7799762B2 (en) 2010-09-21
HUP0204531A2 (hu) 2003-06-28
EP1242365A1 (fr) 2002-09-25
AU2857201A (en) 2001-07-03
WO2001046126A1 (fr) 2001-06-28
WO2001046127A1 (fr) 2001-06-28
US20100215685A1 (en) 2010-08-26
US8173133B2 (en) 2012-05-08
AU2006202085A1 (en) 2006-06-15
RU2002119418A (ru) 2004-01-10
AR035024A1 (es) 2004-04-14
CN1434795B (zh) 2012-11-14

Similar Documents

Publication Publication Date Title
BR0016696A (pt) Pseudo-dipeptìdeos acilados inéditos portadores de um ramo auxiliar funcionalizado, processos para a sua preparação e composições farmacêuticas contendo-os
BR9910066A (pt) Composição farmacêutica fluida que permite a liberação controlada de pelo menos uma substância ativa, processo de fabricação de uma composição farmacêutica, e, utilização de uma composição
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR9813811A (pt) "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo"
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
BR0112986A (pt) Compostos azabicìclicos, o respectivo preparo e a respectiva utilização como medicamentos, notadamente como antibacteriano
BR0014563A (pt) Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica
BG101118A (en) Therapeutical compounds
PT80828B (pt) Processo para a preparacao de composicoes farmaceuticas contendo uma mistura de, pelo menos, um derivado de xantina com acido o-acetilsalicilico ou os seus sais farmaceuticamente aceitaveis
MX9704745A (es) Derivados de piperazina, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
ATE196605T1 (de) Gruppe a streptokokkenpolysaccharide immunogen- zusammensetzungen und verfahren
ATE247985T1 (de) Einführung einer thiol-gruppe in proteine für die radioimmundetektion und radioimmuntherapie auf der basis von radionukliden
AR011957A1 (es) Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal
Bailey et al. Nalidixic acid arthralgia
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas
PH12021551226A1 (en) Monomethyl fumarate-carrier conjugates and methods of their use
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
BR0215124A (pt) Compostos e seus usos, composições farmacêutica e cosmética e uso cosmético de uma composição cosmética
MX9102101A (es) Composiciones que contienen psyllium. composiciones que contienen psyllium.
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
BR0014233A (pt) Conjugados de 4-benzilaminoquinolina com ácido galênico e seus heteroanálogos, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
NO179094C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat for påföring på slimhinnen
ES2109208T1 (es) Nuevas aplicaciones de un dimero de lisozima.
FR2574404B1 (fr) Derives 1-substitues de l'acide 6-fluoro-7-(pyrrol-1-yl)-1,4-dihydro-4-oxoquinoleine-3-carboxylique, leur preparation et leur application en tant que medicaments
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 14A E 15A ANUIDADES.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.